Sure hope our PH results bring them back to life in this arena; their PAH is failing.
8-24-11, FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
http://ir.unither.com/releases.cfm
And Can you believe this:
I wrote back saying, ''That makes no sense - I saw and read it in your PR section right after the deal.''
| From: |
Andy Fisher <Andy@unither.com>
Add to Contacts
|
| To: |
"alertid@att.net" <alertid@att.net> |
|
Thanks, but that was actually not our press release, so it wouldn't normally appear in our news section.
#cg_msg_content { font-family:arial, helvetica, sans-serif;}#cg_msg_content h1 {font-size:14px;}#cg_msg_content p,#cg_msg_content ul,#cg_msg_content td,#cg_msg_content th {font-size:12px;text-align:left;}#cg_msg_content small{font:10px Verdana;color:#ccc;}#cg_msg_content a{font-size:12px;text-align:left;}
The following comment was submitted via the United Therapeutics Corporation website by tim [alertid@att.net].
Your News section is missing the June 30 2011 PR with Pluristem.
Respectfully,
ts
United Therapeutics Corporation
1040 Spring Street
Silver Spring, MD 20910
